Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Radiopharm Theranostics LtdRADX · Entity 7436 | Chief Medical Officer | March 18, 2026 | May 07, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | SVP, Clinical Development | February 10, 2022 | February 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Radiopharm Theranostics Ltd
Report date March 18, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-07-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-07-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-07-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
Zentalis Pharmaceuticals, Inc.
Report date February 10, 2022 · Filed February 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,978 |
Ending reported balance
After 2022-02-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-02-10 · Grant · Acquired 10,329 · Balance 16,579 F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Row 2 · 2022-02-14 · Sale · Disposed 534 · Balance 16,045 F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-02-14 · Sale · Disposed 67 · Balance 15,978 F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.61 · Expires 2032-02-09 | Direct | 24,234 |
Reported balance
After 2022-02-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-10 · Grant · Acquired 24,234 · Balance 24,234 F5: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 67 | $50.75 | $3,400.06 |
DisclosureSEC source: 0001725160-22-000035 · wf-form4_164489102664442.xml · nonDerivative · entry 3 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,978 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 534 | $50.16 | $26,787.68 |
DisclosureSEC source: 0001725160-22-000035 · wf-form4_164489102664442.xml · nonDerivative · entry 2 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,045 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 24,234 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001725160-22-000035 · wf-form4_164489102664442.xml · derivative · entry 4 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,234 Underlying: Common Stock · 24,234 shares Expires 2032-02-09 F5 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 10,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000035 · wf-form4_164489102664442.xml · nonDerivative · entry 1 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,579 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · derivative · entry 15 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,949 Underlying: Common Stock · 10,000 shares Expires 2030-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F11 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,657 | $61.21 | $101,419.17 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 12 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F10 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.01 to $61.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,343 | $60.52 | $504,904.18 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 11 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,907 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.00 to $60.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 10 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · derivative · entry 14 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,949 Underlying: Common Stock · 10,000 shares Expires 2030-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F11 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 555 | $62.24 | $34,540.54 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 9 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $62.15 to $62.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,556 | $61.51 | $95,707.23 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 8 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,805 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.09 to $61.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,889 | $60.55 | $477,682.89 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 7 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,361 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.07 to $61.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 6 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · derivative · entry 13 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,949 Underlying: Common Stock · 10,000 shares Expires 2030-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F11 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,300 | $64.66 | $84,063.98 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 5 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.23 to $65.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,997 | $63.48 | $126,767.36 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 4 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,550 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $63.18 to $64.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,294 | $62.34 | $205,334.13 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 3 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,547 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.98 to $62.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,409 | $61.70 | $210,325.75 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 2 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,841 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.97 to $61.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | Exercise / conversionCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001725160-22-000015 · wf-form4_164272409240773.xml · nonDerivative · entry 1 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001725160-21-000037 · wf-form4_161352006609320.xml · derivative · entry 2 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2031-02-10 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000037 · wf-form4_161352006609320.xml · nonDerivative · entry 1 Voliotis Dimitris · CIK 0001807910 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.